Aharon Schwartz Acquires 50,000 Shares of Foamix Pharmaceuticals Ltd (FOMX) Stock

Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Director Aharon Schwartz bought 50,000 shares of the stock in a transaction dated Monday, November 26th. The shares were purchased at an average price of $3.89 per share, with a total value of $194,500.00. Following the completion of the transaction, the director now directly owns 50,000 shares in the company, valued at approximately $194,500. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Aharon Schwartz also recently made the following trade(s):

  • On Wednesday, November 28th, Aharon Schwartz bought 12,200 shares of Foamix Pharmaceuticals stock. The shares were purchased at an average price of $3.88 per share, with a total value of $47,336.00.

NASDAQ FOMX opened at $4.00 on Thursday. The company has a market cap of $217.13 million, a PE ratio of -2.27 and a beta of 2.07. Foamix Pharmaceuticals Ltd has a one year low of $3.60 and a one year high of $7.60.

Foamix Pharmaceuticals (NASDAQ:FOMX) last posted its earnings results on Wednesday, November 7th. The specialty pharmaceutical company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.07). The firm had revenue of $0.87 million for the quarter, compared to the consensus estimate of $1.10 million. Foamix Pharmaceuticals had a negative net margin of 2,049.92% and a negative return on equity of 118.29%. On average, sell-side analysts predict that Foamix Pharmaceuticals Ltd will post -1.65 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Orbimed Advisors LLC raised its holdings in Foamix Pharmaceuticals by 223.2% during the 2nd quarter. Orbimed Advisors LLC now owns 4,040,000 shares of the specialty pharmaceutical company’s stock valued at $20,240,000 after buying an additional 2,790,000 shares during the period. First Manhattan Co. raised its holdings in Foamix Pharmaceuticals by 1,664.3% during the 3rd quarter. First Manhattan Co. now owns 617,500 shares of the specialty pharmaceutical company’s stock valued at $3,538,000 after buying an additional 582,500 shares during the period. C WorldWide Group Holding A S purchased a new stake in Foamix Pharmaceuticals during the 3rd quarter valued at $3,438,000. AXA raised its holdings in Foamix Pharmaceuticals by 43.8% during the 3rd quarter. AXA now owns 1,369,341 shares of the specialty pharmaceutical company’s stock valued at $7,846,000 after buying an additional 416,787 shares during the period. Finally, Monashee Investment Management LLC purchased a new stake in Foamix Pharmaceuticals during the 3rd quarter valued at $1,719,000. Hedge funds and other institutional investors own 62.84% of the company’s stock.

FOMX has been the subject of a number of research reports. Cowen set a $30.00 target price on Foamix Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, November 7th. Zacks Investment Research upgraded Foamix Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.75 target price for the company in a research report on Wednesday, September 19th. HC Wainwright reiterated a “buy” rating and set a $14.00 target price (up from $12.00) on shares of Foamix Pharmaceuticals in a research report on Wednesday, September 12th. BidaskClub upgraded Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, October 18th. Finally, Cantor Fitzgerald initiated coverage on Foamix Pharmaceuticals in a research report on Thursday, October 11th. They set an “overweight” rating for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $13.94.

COPYRIGHT VIOLATION WARNING: This story was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/12/06/aharon-schwartz-acquires-50000-shares-of-foamix-pharmaceuticals-ltd-fomx-stock.html.

About Foamix Pharmaceuticals

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus.

Recommended Story: Do stock splits help investors?

Insider Buying and Selling by Quarter for Foamix Pharmaceuticals (NASDAQ:FOMX)

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply